Medicare Advantage and Cancer Surgery Outcomes: Are Patients Being Routed Away from High-Quality Hospitals?
Posted inAI General Surgery Oncology Specialties

Medicare Advantage and Cancer Surgery Outcomes: Are Patients Being Routed Away from High-Quality Hospitals?

This retrospective national cohort study reveals that Medicare Advantage (MA) enrollees undergoing major cancer surgery are less likely to receive care at high-quality hospitals compared to traditional Medicare beneficiaries, raising concerns about MA networks' impact on access to optimal surgical care.
Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial
Posted inOB/GYN & Women's Health Oncology Radiology Specialties

Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial

This clinical trial prospectively evaluates how a 12-gene expression assay (DCIS score) guides postoperative radiotherapy decisions after breast-conserving surgery in ductal carcinoma in situ, showing tailored radiotherapy use may reduce ipsilateral breast events.
Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives
Posted inAI Oncology Pathology & Lab Medicine Specialties

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives

AI-detected tumor-infiltrating lymphocytes on routine histology independently predict response and survival in advanced melanoma treated with anti-PD-1 therapies, outperforming manual scoring and offering an accessible biomarker for immune checkpoint inhibitor outcomes.
Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis
Posted inClinical Updates news Oncology Urology

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients ineligible for cisplatin, with manageable safety.
Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial
Posted innews Oncology Urology

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiotherapy alone, with limited toxicity.
Safety and Activity of Tarlatamab Combined with PD-L1 Inhibitors as First-Line Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: Insights from the DeLLphi-303 Phase 1b Study
Posted inOncology

Safety and Activity of Tarlatamab Combined with PD-L1 Inhibitors as First-Line Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: Insights from the DeLLphi-303 Phase 1b Study

This review synthesizes evidence on tarlatamab plus PD-L1 inhibitors as maintenance therapy post chemo-immunotherapy in extensive-stage SCLC, highlighting safety, clinical activity, and translational implications from the DeLLphi-303 study and contextual literature.